State of the art and emerging drug therapies for female infertility

Roberta Venturella, Alberto Vaiarelli, Danilo Cimadomo, Sara Pedri, Daniela Lico, Rossella Mazzilli, Rita Mocciaro, Laura Rienzi, Costantino Di Carlo, Filippo Maria Ubaldi, Fulvio Zullo
In: Gynecological Endocrinology · 2019 · vol. 35(10) , pp. 835–841 · doi:10.1080/09513590.2019.1603289 · PMID:31032671 · W2943645399
review OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This review examines current and emerging drug therapies for female infertility, focusing on reducing treatment burden and risks through repurposing existing drugs and developing new compounds.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

fertilization (IVF) has become the standard approach to treat this condition but a thorough investigation and, whenever possible, the individual diagnosis of the underlying causes of infertility are required. For many female causes, indeed, efficient medical therapies are available to achieve a fast solution of the problem. This review is based on the relevant literature indexed in PubMed and SCOPUS and is focused on the most recent clinical literature on the treatment of women (and couples) affected from infertility. The reduction in IVF treatment burden and risks are now considered pivotal to set 'patient-friendly' therapies and represent crucial issues for both patients and physicians. To this end, the researchers are now focusing their attention on old drugs with new indications and new compounds with more appropriate functions, to improve the compliance of the women and reduce the burden of infertility, a condition that is becoming an important issue in the modern world, also for the Public Health System.

My notes (saved in your browser only)

Condition tags

infertility

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (80)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK